Chris Somogyi to Lead Know Labs’ International Business

Know Labs Inc. has welcomed a new member to its top management team, appointing Chris Somogyi as president, International. 

With more than 40 years of experience in commercializing innovation across related industries, Somogyi will lead the company’s “Skunkworks” Program and global patent licensing efforts. In his new role, Somogyi will focus on identifying new applications of Know Labs’ intellectual property (IP) portfolio, which consists of more than 300 patents issued, pending and in-process and covering over 100 medical and non-medical applications. As part of his responsibilities, he also will work with potential strategic partners and customers on a Rest of the World (RoW) product that uses Know Labs’ continuous glucose monitor—the KnowU—as a screening device to support diagnoses in large, diverse populations across Asia, Africa, South America, and the Middle East (where diabetes incidence is at near pandemic levels).

Somogyi has an extensive background in biomedical engineering and product innovation, with over 20 issued patents to his name. His experience includes managing intellectual property at Stanford University, leading innovation grant funds for the New Zealand government and holding product development and incubation roles at organizations such as SRI International and Xerox PARC (Palo Alto Research Center). At the world’s largest IP fund, the $6 Billion Intellectual Ventures, Somogyi co-managed a $750 million global invention fund. He has served as a partner in medical and agricultural technology funds in the United States and Japan. His experience in technology monetization has an expansive global reach. His practical experience is built upon a bachelor of science degree in biomedical engineering from Purdue, a master’s degree in biomedical engineering from Tulane, and an MBA from the University of Washington.

“We are thrilled to welcome Chris Somogyi to our executive team as president, International,” Know Labs CEO/Board Chairman Ron Erickson said. “His expertise in commercialization of IP and his track record of driving innovation and building strategic partnerships make him an invaluable addition to our company. With Somogyi’s leadership, we are moving aggressively with our ‘Skunkworks’ Program to derive revenue in worldwide markets from the significant IP portfolio surrounding our platform technology.”

Somogyi’s appointment as president, International, allows the company to maintain its core focus on bringing the first non-invasive continuous glucose monitor to the marketplace. While the company moves toward U.S. Food and Drug Administration clearance of its technology, Somogyi will work to drive revenue from non-core fields of use of the Know Labs platform technology.

Know Labs Inc. is a public company whose shares trade on the NYSE American Exchange. Its platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels.